FHL1 and hepatocellular carcinoma: While FHL1 is reported to inhibit human liver cancer, a study by Zhou et al.67 showed that FHL1 could effectively promote paclitaxel resistance in HCC cells, both in vitro and in vivo, through inhibition of caspase-3.